TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) today provided an update on the impact of the quality assurance review by the European Medicines Agency (EMA) of Ben Venue Laboratories on the availability of Ceplene® (histamine dihydrochloride).
